Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC
Clinical trial NCT04094909 · UNKNOWN
Trial details
- NCT number
- NCT04094909
- Sponsor
- Guangzhou Institute of Respiratory Disease
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-06
- Primary completion
- 2022-12-31
- Enrollment
- 186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.